VanEck JP Morgan EM Local Currency Bond ETF vs Twist Bioscience Corp — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.64, while Twist Bioscience Corp trades at $123.1 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | TWST | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $124.88 |
52-Week Low | $24.83 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.655, up 0.14% with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent dividend distributions, with recent payouts of $0.14 in June 2026. Support and resistance cluster around $26, indicating a key price level. Financial ratios are not provided in the snapshot, limiting fundamental assessment.
Outlook hinges on emerging market debt dynamics and Federal Reserve policy, as noted in recent news. Risks include volatility from macroeconomic shifts and regional instability. The technical setup suggests near-term stability, but fundamental clarity is needed for long-term confidence.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →